Up­dat­ed: Bio­Marin’s he­mo­phil­ia A gene ther­a­py Roc­ta­vian wins FDA ap­proval af­ter de­lay and re­jec­tion, priced at $2.9M

The FDA ap­proved the first gene ther­a­py to treat the ge­net­ic bleed­ing dis­or­der he­mo­phil­ia A on Thurs­day, cap­ping a tur­bu­lent reg­u­la­to­ry saga for Bio­Marin, which will now turn to com­mer­cial­iz­ing the one-time treat­ment.

Se­cur­ing the ap­proval for Roc­ta­vian was no easy feat. There was a sur­prise re­jec­tion in 2020 and a re­view ex­ten­sion ear­li­er this year, and now Bio­Marin has to sell the ther­a­py, which it hopes can grow in­to a key block­buster drug that can help dou­ble com­pa­ny rev­enues to $4 bil­lion to $5 bil­lion by the mid­dle of the decade. The drug­mak­er record­ed rev­enues of about $2.1 bil­lion last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER